Rapid Inpatient Methadone Induction in the Fentanyl Era: A Systematic Review of Safety, Efficacy, and Protocols for Hospitalized Patients with Opioid Use Disorder
Abstract
The potency of illicit fentanyl has rendered standard methadone inductions inadequate for many hospitalized adults with opioid use disorder. Standard protocols often fail to achieve therapeutic doses quickly enough to manage withdrawal and cravings in fentanyl-tolerant individuals, contributing to poor retention and higher self-discharge rates. This review examines emerging evidence on dosing strategies, outcomes, and safety of rapid methadone inductions in acute-care hospitals. Nine studies (five retrospective cohorts, four case series/reports) encompassing 380 patients met inclusion criteria. Median starting doses were 30–40 mg (range 20–90 mg), with daily or symptom-triggered increases achieving 60–100 mg within 5–7 days—substantially faster than outpatient schedules. Sedation occurred in 6.4% of patients, while severe sedation requiring naloxone or ICU transfer was rare (0.4%). No in-hospital deaths, malignant arrhythmias, or torsades de pointes were reported. The only study assessing post-discharge outcomes found no overdoses within 30 days. Rapid titration improved retention, with self-discharge against medical advice ranging from 4 to 19% overall and significantly lower among pregnant patients than with slower titration (23.0% vs. 37.9%). Pregnant individuals, those with infections, and polysubstance users tolerated rapid induction without excess adverse events. Observational data suggest that rapid inpatient methadone titration can safely and effectively reach…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 380 participants or records.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.